- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Skeletal system.
Displaying page 1 of 5.
EudraCT Number: 2008-000040-13 | Sponsor Protocol Number: 21011075118 | Start Date*: 2009-02-11 |
Sponsor Name:Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie | ||
Full Title: Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia | ||
Medical condition: Friedreich's ataxia (FRDA) is the most common autosomal recessive neurodegenerativ disease (1:50 000) affecting the central and peripheral nervous system. Extraneural organs are also affected durin... | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002024-28 | Sponsor Protocol Number: 0-001-FR | Start Date*: 2008-03-18 | |||||||||||
Sponsor Name:POLICLINICO SAN DONATO IRCSS | |||||||||||||
Full Title: QUIXIL VALIDATION IN HIP REPLACEMENT FIRST IMPLANT | |||||||||||||
Medical condition: Hip arthitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016873-13 | Sponsor Protocol Number: PTHinCharcotfoot | Start Date*: 2010-04-29 | |||||||||||
Sponsor Name:King’s College Hospital NHS Foundation Trust | |||||||||||||
Full Title: A novel therapy using recombinant human PTH 1-84 to stimulate bone repair and enhance fracture healing in the acute Charcot foot: a double blind placebo controlled phase IV trial | |||||||||||||
Medical condition: Charcot osteoarthropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004566-16 | Sponsor Protocol Number: CSPP100A2238 | Start Date*: 2007-03-12 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patie... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-007276-41 | Sponsor Protocol Number: Ram_GEP_1 | Start Date*: 2008-05-13 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril | ||
Medical condition: healthy young males | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002633-38 | Sponsor Protocol Number: 08781 | Start Date*: 2018-11-19 |
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children. | ||
Medical condition: Metaphyseal chondrodysplasia type Schmid (MCDS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002721-29 | Sponsor Protocol Number: 08486 | Start Date*: 2018-12-24 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy | ||
Medical condition: Mitochondrial Myopathy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2010-021463-32 | Sponsor Protocol Number: IC-01-02-02-007 | Start Date*: 2011-02-24 | |||||||||||
Sponsor Name:Innovacell Biotechnologie AG | |||||||||||||
Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-finding clinical study | |||||||||||||
Medical condition: Fecal incontinence in female and male patients with external anal sphincter weakness or sphincter damage. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) SI (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018975-13 | Sponsor Protocol Number: ROSA_10 | Start Date*: 2010-02-24 | |||||||||||
Sponsor Name:ISTITUTO ORTOPEDICO RIZZOLI | |||||||||||||
Full Title: EFFICACY OF ROSE HIP IN TREATMENT OF PAIN IN PATIENTS WITH COXARTHROSIS | |||||||||||||
Medical condition: PATIENTS TO BE IMPLANTED WITH HIP PROSTHESIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002590-38 | Sponsor Protocol Number: 17777 | Start Date*: 2016-12-14 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastati... | |||||||||||||
Medical condition: Metastatic hormone-sensitive prostate cancer (mHSPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) BE (Completed) ES (Completed) FI (Completed) DE (Completed) CZ (Completed) NL (Completed) PL (Completed) FR (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021871-10 | Sponsor Protocol Number: IC-01-01-05-004 | Start Date*: 2012-04-18 | |||||||||||
Sponsor Name:Innovacell Biotechnologie AG - Life Science Center Innsbruck | |||||||||||||
Full Title: A multicenter, randomized, double-blinded, parallel-group, placebocontrolled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin... | |||||||||||||
Medical condition: Stress urinary incontinence (SUI) of moderate severity (Grade 2 and Grade 3) in female patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) BG (Completed) AT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003512-30 | Sponsor Protocol Number: ASB-008 | Start Date*: 2007-04-05 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI) | |||||||||||||
Medical condition: Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002512-27 | Sponsor Protocol Number: NL44774.068.13 | Start Date*: 2013-11-25 |
Sponsor Name:Maastricht University | ||
Full Title: The role of bile acids in human brown adipose tissue metabolism | ||
Medical condition: Healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024659-10 | Sponsor Protocol Number: 2010-024659-10 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition? | |||||||||||||
Medical condition: Muscular dystrophy with nNOS insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002123-32 | Sponsor Protocol Number: 56/2007/U/Sper | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Use of Bone Morphogenic Protein 7 in the atrophic maxilla | |||||||||||||
Medical condition: bone atrophy of the maxilla | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001910-88 | Sponsor Protocol Number: ATYR1940-C-004 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:aTyr Pharma, Inc. | |||||||||||||
Full Title: An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Facioscapulohumeral Musc... | |||||||||||||
Medical condition: Limb Girdle Muscular Dystrophy and Facioscapulohumeral Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003060-40 | Sponsor Protocol Number: TICSI | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | |||||||||||||
Full Title: Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition | |||||||||||||
Medical condition: Adverse effects of prescribed glucocorticoid therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000469-19 | Sponsor Protocol Number: BUR-CL207 | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd. | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Ag... | |||||||||||||
Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burnett ... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Prematurely Ended) SE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001489-17 | Sponsor Protocol Number: SIOPENRNET003 | Start Date*: 2006-11-17 |
Sponsor Name:St. Anna Kinderkrebsforschung e.V. | ||
Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) | ||
Medical condition: High Risk Neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Ongoing) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003146-41 | Sponsor Protocol Number: 50021031-2 | Start Date*: 2007-03-08 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin Berlin; Department of Rheumatology and Clinical Immunology | |||||||||||||
Full Title: A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHO... | |||||||||||||
Medical condition: Musculoskeletal disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
